Nuclera Nucleics
Financials
Estimates*
GBP | 2021 | 2022 |
---|---|---|
Revenues | <1m | <1m |
% growth | - | 9872 % |
EBITDA | (3.0m) | (4.9m) |
% EBITDA margin | (179534 %) | (2961 %) |
Profit | (4.7m) | (5.8m) |
% profit margin | (286316 %) | (3498 %) |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | £100k | Grant | |
N/A | £25.0k | Grant | |
N/A | £203k | Grant | |
N/A | $10.0m | Late VC | |
* | $42.5m | Series B | |
* | $15.5m | Series B | |
* | £1.1m | Grant | |
Total Funding | €63.5m |
Recent News about Nuclera Nucleics
EditNuclera is a biotechnology company specializing in on-demand gene to protein synthesis, enabling scientists to create, build, and engineer biology directly in their own laboratories. The company serves researchers and scientists in the field of synthetic biology, providing high-quality genes and proteins with a focus on speed, flexibility, and accuracy. Nuclera operates in the synthetic biology market, leveraging a biologically inspired platform that allows for the rapid construction of genes, often within a day. The business model revolves around selling its proprietary technology and related services to laboratories and research institutions, generating revenue through the sale of its synthesis platform and consumables. By making gene and protein writing accessible and customizable, Nuclera aims to revolutionize the way biological research is conducted.
Keywords: gene synthesis, protein synthesis, synthetic biology, biotechnology, laboratory tools, research, high accuracy, customization, rapid construction, benchtop technology.